Voyager Therapeutics, Inc.
VYGR
Rank in Stocks
#18801
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating... Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.
Share Price
$1.99
Last synced: 2026-11-09
Market Cap
$122.62M
Change (1 day)
6.70%
Change (1 year)
-53.18%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Voyager Therapeutics, Inc. (VYGR)
Category
Healthcare
Operating Margin for Voyager Therapeutics, Inc. (VYGR)
Operating Margin as of November 2026 TTM: -340.08%
According to Voyager Therapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is -340.08%. At the end of 2025 the company had an operating margin of -326.56%.
Operating Margin history for Voyager Therapeutics, Inc. from 2013 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -340.08% | 4.14% |
| 2025 | -326.56% | 213.67% |
| 2024 | -104.11% | -313.34% |
| 2023 | 48.80% | -139.27% |
| 2022 | -124.27% | -36.84% |
| 2021 | -196.76% | -1,329.75% |
| 2020 | 16.00% | -132.32% |
| 2019 | -49.51% | -95.86% |
| 2018 | -1,195.63% | 68.62% |
| 2017 | -709.06% | 144.14% |
| 2016 | -290.43% | 148.55% |
| 2015 | -116.85% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.11% |
US
|
|
| -149.01% | -99.56% |
US
|
|
| 25.57% | -100.08% |
AU
|
|
| 31.23% | -100.09% |
BE
|
|
| 29.35% | -100.09% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Voyager Therapeutics, Inc.'s operating margin
What is Voyager Therapeutics, Inc.'s operating margin?
Voyager Therapeutics, Inc.'s operating margin is -340.08%, as of Nov 2026.
What was Voyager Therapeutics, Inc.'s operating margin in 2025?
In 2025, Voyager Therapeutics, Inc.'s operating margin was -326.56%, compared with -104.11% in 2024.
How has Voyager Therapeutics, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Voyager Therapeutics, Inc.'s operating margin was highest in 2023 (48.80%) and lowest in 2025 (-326.56%).
How does Voyager Therapeutics, Inc.'s operating margin compare with similar companies?
Voyager Therapeutics, Inc.'s operating margin (-340.08%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.